Emmaus Life Sciences to Participate in the Piper Jaffray Healthcare Conference
TORRANCE, Calif.--(BUSINESS WIRE)-- Emmaus Life Sciences, Inc. (Emmaus), a leader in sickle cell disease treatment, announced today that its CEO, Yutaka Niihara, MD, MPH will present at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018, at 8:50 a.m. ET in New York, New York. A webcast of the event will be available at https://bit.ly/2P49yYl.
About Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. Its lead product, EndariTM (L-glutamine oral powder), demonstrated positive clinical results in the completed Phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia and has received U.S. FDA approval. Visit: http://www.emmausmedical.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181126005776/en/
LaVoie Health Science
Katie Gallagher, 617-374-8800 x109
kgallagher@lavoiehealthscience.com
Source: Emmaus Life Sciences, Inc.
Released November 26, 2018